Colorectal cancer
Conditions
Interventions
Bevacizumab group:Standard late-stage first-line postoperative adjuvant chemotherapy
Sponsors
Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Pathologically confirmed as stage IV metastatic colorectal cancer; (2) Planned to receive initial treatment with FOLFIRI/FOLFOX combined with bevacizumab/cetuximab; (3) Age =18 years; (4) Expected survival =3 months; (5) Normal cognitive function and able to cooperate with the study; (6) Signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Severe gastrointestinal diseases (e.g., intestinal perforation infection, Crohn's disease, ulcerative colitis) or autoimmune diseases; (2) Severe cardiovascular diseases (e.g., myocardial infarction, heart failure (NYHA III–IV class), stroke, uncontrolled hypertension (systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg), etc.), liver or kidney failure, or hematological diseases; (3) History of drug or alcohol abuse; (4) Pregnancy or breastfeeding; (5) Use of antibiotics or probiotic formulations within 2 weeks prior to treatment; (6) Participation in other drug clinical trials within the past 3 months; (7) Planned radiotherapy; (8) Assessed by the investigator as unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Colorectal Surgical Tissue Sections Omics Analysis;Blood Metabolomics, Genomics, Proteomics; | — |
Countries
China
Contacts
Public ContactYAO Qinghua
The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province
Outcome results
None listed